Skip navigation

Please visit our News & Updates. Sign up here to receive news updates via email.

The Power of NAi – Our AI-Powered Platform

With five drug candidates phase II/III ready and over a hundred drug and diagnostic targets discovered, BPGbio is leading the field in putting the first AI-developed drug onto the market and proving the concept of AI drug discovery. NAi discoveries have consistently led to successful clinical trials.

AI Drug Discovery

Protein Homeostasis

BPGbio’s Protein Homeostasis program is built around a First-In-Class ubiquitin conjugating enzyme (E2) based targeted protein degradation (TPD) platform (“E2 Platform”).

Protein Homeostasis

Discoveries made using the NAi Interrogative Biology Platform have consistently led to successful clinical trials.

Clinical Trials

Clinical trials are where innovation meets verification. The progress BPGbio is making in clinical trials represents the strongest testament to the efficacy of our AI-powered drug discovery platform – the NAi Interrogative Biology® platform.

Pancreatic Cancer  Glioblastoma (GBM)  Epidermolysis Bullosa (EB)  Sarcopenia   Chemo-Induced Alopecia (CIA)

A Robust & Growing Pipeline

As a biotech company, BPGbio’s mission is to deliver more optimized medicine for a healthier future. Harnessing unbiased data from our own biobank and leveraging purposely built AI, we are developing a range of transformative therapies aimed at addressing unmet medical needs.

Pipeline

Partner with Us

We invite forward-thinking organizations to partner with us. Whether it’s licensing our assets or harnessing the power of NAi for new discovery, we’re committed to creating strong relationships that drive success.

Work With Us

Patents

With over 400 US and international patents, BPGbio’s intellectual property portfolio reinforces our leadership in bioscience, offering partners and investors a foundation of exclusivity and fostering revolutionary advancements in the healthcare landscape.

Explore Our Patents